Boston, MA 10/06/2014 (wallstreetpr) – Durata Therapeutics Inc (NASDAQ:DRTX) has agreed to be purchased by Actavis plc (NYSE:ACT). The deal is expected to complete later this year or early next year. DRTX has been offered $23 per share, which suggests 66% premium from the previous closing price before the deal was made public. The companies said […]
